Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics, Inc.는 임상 단계 바이오 제약 회사로, 미국에서 면역 염증성 질환 치료를 위한 신규 분자 물질 후보를 발굴하고 개발하는 데 주력하고 있습니다. 당사의 제품 파이프라인에는 중등도에서 중증 아토피 피부염, 천식, 비강 용종을 동반한 만성 비부비동염, 중등도에서 중증 만성 폐쇄성 폐질환 치료를 위한 임상 2상 시험 중인 항-흉선 기질 림프포이에틴 단일클론 항체인 Bosakitug (ATI-045); T세포 매개 자가면역 질환 치료를 위한 임상 2a상 시험 중인